In 2020 Darnitsa Introduced 10 New Brands to the Market15 January 2021
In 2020 Darnitsa presented 10 new brands in the cardiological, neurological and other therapeutic classes.
The company invested 24% of the gross profit in the development and research of medicinal products.
Launches of 2020 also include antibacterial therapy, mental health, treatment of diseases of the respiratory system and musculoskeletal system. In the category of over-the-counter drugs, marketing authorization was obtained for a mucolytic of plant origin Ritosse® Plantain and composing drug Hipnos®.
In the category of prescription drugs, Darnitsa presented Efstat® - a drug for the treatment of gout and inhibition of uric acid production; Alfakholin® - for the treatment of cognitive disorders in cases of injury of the central nervous system; a unique injectable combination painkiller Neospastil®; a medication for the treatment of hypertension and prevention of myocardial infarction Tiara Solo®; a drug for enhancing mental performance and normalizing sleep Glycine-Darnitsa.
Out of category but according to standards for medicines, Darnitsa has developed and registered a broad-spectrum antiseptic Darsept®, which was developed taking into account the recommendations of the WHO.
Dmytro Shymkiv, Chairman of the Board of Directors of Darnitsa Group:
“Darnitsa’s mission as the market leader is to provide patients with effective and affordable medicines. During 2015-2019, Darnitsa launched more than 40 pharmaceutical brands, investing about UAH 1 billion in the development of new medicines. To meet the growing needs of the market and respond quickly to new demands in 2020, the company has switched to flexible production planning, ensures the availability of strategic stocks of pharmaceutical substances and has implemented employee safety measures. At the same time, Darnitsa’s digital transformation continues, giving us flexibility in responding to changes in demand and increasing the accuracy of planning the process of developing and conducting clinical trials.”
Despite global challenges, Darnitsa’s product strategy remains the same - to provide effective treatment for cardiovascular and nervous system diseases, as well as pain management. The efficacy, therapeutic equivalence and safety of each new product are proven by Darnitsa in bioequivalence studies. During 2018-2020, 8 such studies were completed, the vast majority of which were conducted in the EU.